source
- BioNTech's CTLA-4 antibody gotistobart shows 8.5-month survival boost in previously treated lung cancer patientsBioNTech reported new data on its CTLA-4 targeting antibody gotistobart in lung cancer. The study focused on patients whose disease had progressed after prior therapy. Those receiving gotistobart…
- BioNTech's anti-CTLA-4 drug shows survival advantage in advanced squamous lung cancer at WCLCBioNTech, together with partner OncoC4, presented new overall survival data at the World Conference on Lung Cancer in South Korea, joining other companies such as Summit Therapeutics, GSK and Roche…